课题基金 / 基金详情

In vitro chemosensitivity by MTT assay and clinical outcomes in childhood leukemia

In vitro chemosensitivity by MTT assay and clinical outcomes in childhood leukemia
MTT 测定的体外化疗敏感性和儿童白血病的临床结果
批准号:
05670667
负责人:
HONGO Teruaki
金额:
$1.34万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1995

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We investigated the relationship between in vitro sensitivity and clinical outcomes in 196 children with newly diagnosed ALL.We explored whether the sensitivity to a combination of four drugs DPAV (Dex, Pred, Asp, VCR) predicted induction failure and early relapse (IF/e.rel). [Patients and Methods] Eligible were children (age 0-16 years) with non-B cell ALL,newly diagnosed between 1989 and 1995. BM samples were sent for in vitro drug tests. There were 142 samples of common ALL (cALL), 21 of T-ALL,28 of mixed lineage ALL (mix ALL) and 5 of undifferentiated ALL (uALL). All patients (pts) were treated with the ALL protocol of Pred, Asp and VCR for standard risk, plus CPA and DNR for high risk, as induction therapy. In vitro tests were carried out with a four-day culture and MTT assay. We tested 16 drugs and calculated LD70 for 14 drugs, and LCS for Dex and Pred.For each single drug, pts were classified into two groups, as either S (lower than median LD70 or LCS) or R (higher than median L … More D70 or LCS).[Statistics] The Kaplan-Meier method for EFS,log rank test, Fisher's PLSD,and contingency table analysis for multi-variate comparison were conducted using Stat View-J4.5 (Abacus Concepts).[Results] EFS (3 yrs) of pts with cALL,T-ALL,mix ALL,uALL were 0.727,0.560,0.534,0.600 respectively. S group pts for Pred, VP16, VCR and MIT had superior EFS to R group pts (p<0.05). When we classified pts into three groups (S,I,R) by sensitivity to four drugs (DPAV), EFS (3 yrs) of S group (n=41) was 0.833, that of I (n=78) was 0.752, and that of R (n=74) was 0.546 (p=0.0011). Then we investigated whether the drug sensitivity of S or R was related to three prognostic groups (CCR,IF/e.rel, late relapse). S groups of Pred, BLM,VP16, VCR,MIT were significantly related to CCR,and R to IF/e.rel (p<0.05). When we used S,I and R for DPAV sensitivity, S and I pts tended to maintain CCR,and R pts tended to undergo IF/e. rel and late relapse (p=0.004). [Conclusion] In vitro drug sensitivity testing together with immunological marker testing provides prognostic information for childhood ALL. Less
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
T.Matsushita, N.Ogawa, S.Yajima, T.Hongo: "In vitro assay results of 15 children with Ph1 positive ALL and their clinical outcomes." Leukemia. 9 (3). 543 (1995)
T.Matsushita、N.Okawa、S.Yajima、T.hongo:“15 名 Ph1 阳性 ALL 儿童的体外检测结果及其临床结果。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
矢島周平、本郷輝明: "Ewing肉腫と骨髄移植併用療法" 小児外科. 27. 1212-1217 (1995)
Shuhei Yajima、Teruaki Hongo:“尤文氏肉瘤和骨髓移植联合治疗”小儿外科。 27. 1212-1217 (1995)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
本郷輝明: "抗癌剤耐性機序と多剤併用療法" 小児内科. 25. 959-963 (1993)
Teruaki Hongo:“抗癌耐药机制和多药治疗”小儿内科 25. 959-963 (1993)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Hongo, H.Tsuchiya, S.Yajima, T.Matsushita, S.S.El-Sonbaty, I.Matsuda: "B lineage ALL cells change their anticancer drug resistance profiles after transfection of G-CSF receptor cDNA." Leukemia. 9 (3). 543 (1995)
T.Hongo、H.Tsuchiya、S.Yajima、T.Matsushita、S.S.El-Sonbaty、I.Matsuda:“B 系 ALL 细胞在转染 G-CSF 受体 cDNA 后改变其抗癌药物耐药性。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
13
    海外基金